Abstract
In a 51-year-old man with hyperthyroidism, elevated plasma TSH levels, and evidence of pituitary tumor, plasma TSH levels decreased from a mean basal value of 11 muU/ml to 6 mu/u/ml during the infusion of 200 mug of somatostatin in 60 min. Thyrotropin releasing factor failed to increase plasma TSH levels. T3 administration failed to supress significantly the elevated thyroid 131I uptake. During T3 administration plasma TSH levels showed a downtrend but were not clearly suppressed. These findings are discussed in light of the pertinent literature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Clinical Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
